Panbela Therapeutics, Inc. (NASDAQ:PBLA – Get Free Report)’s stock price rose 2.3% during trading on Thursday . The company traded as high as $0.25 and last traded at $0.25. Approximately 19,872 shares changed hands during trading, an increase of 6% from the average daily volume of 18,815 shares. The stock had previously closed at $0.24.
Panbela Therapeutics Stock Performance
The stock has a market cap of $1.19 million, a price-to-earnings ratio of 0.00 and a beta of 1.34. The firm’s 50-day simple moving average is $0.30 and its two-hundred day simple moving average is $0.34.
About Panbela Therapeutics
Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.
Read More
- Five stocks we like better than Panbela Therapeutics
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Turbulence for Joby Shares: What’s Behind the Recent Dip?
- Should You Invest in Penny Stocks?
- Why Carnival Could Be the Ultimate Non-Tech Growth Stock
- What Are Dividend Achievers? An Introduction
- Super Micro Computer Stock Clears New Path Higher on Saudi Orders
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
